JP2000516459A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516459A5
JP2000516459A5 JP1998508844A JP50884498A JP2000516459A5 JP 2000516459 A5 JP2000516459 A5 JP 2000516459A5 JP 1998508844 A JP1998508844 A JP 1998508844A JP 50884498 A JP50884498 A JP 50884498A JP 2000516459 A5 JP2000516459 A5 JP 2000516459A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998508844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516459A (ja
JP4475683B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/012203 external-priority patent/WO1998004727A1/en
Publication of JP2000516459A publication Critical patent/JP2000516459A/ja
Publication of JP2000516459A5 publication Critical patent/JP2000516459A5/ja
Application granted granted Critical
Publication of JP4475683B2 publication Critical patent/JP4475683B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50884498A 1996-07-25 1997-07-15 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス Expired - Lifetime JP4475683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68628096A 1996-07-25 1996-07-25
US08/686,280 1996-07-25
PCT/US1997/012203 WO1998004727A1 (en) 1996-07-25 1997-07-15 Recombinant pox virus for immunization against tumor-associated antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009171254A Division JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Publications (3)

Publication Number Publication Date
JP2000516459A JP2000516459A (ja) 2000-12-12
JP2000516459A5 true JP2000516459A5 (2) 2005-03-10
JP4475683B2 JP4475683B2 (ja) 2010-06-09

Family

ID=24755674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50884498A Expired - Lifetime JP4475683B2 (ja) 1996-07-25 1997-07-15 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
JP2009171254A Pending JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009171254A Pending JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Country Status (6)

Country Link
US (1) US7410644B2 (2)
EP (2) EP2112225A1 (2)
JP (2) JP4475683B2 (2)
AU (1) AU731860B2 (2)
CA (1) CA2261989C (2)
WO (1) WO1998004727A1 (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
EP1036091B2 (en) * 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
EP1865065A1 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1137792B9 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1864691B1 (en) * 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
US20070196346A1 (en) * 2003-08-21 2007-08-23 Brown Michael P Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
ES2623812T3 (es) 2003-11-12 2017-07-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vectores a medida para tratar y prevenir cáncer pancreático
ES2476990T3 (es) * 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
JP2012515146A (ja) 2009-01-13 2012-07-05 トランジェーヌ、ソシエテ、アノニム 免疫刺激のためのサッカロマイセス・セレビシエのミトコンドリア核酸画分の使用
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
HRP20140262T1 (hr) 2009-04-17 2014-04-25 Transgene Sa Biomarker za praä†enje pacijenata
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
US9804163B2 (en) 2010-08-06 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
WO2015069571A1 (en) * 2013-11-05 2015-05-14 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
JP2017515841A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
JP6851364B2 (ja) 2015-07-31 2021-03-31 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスにおける発現を増強するためのプロモーター
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CA3036799C (en) 2016-09-28 2025-05-13 Bavarian Nordic A/S COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
KR102754876B1 (ko) 2017-08-24 2025-01-13 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020240024A1 (en) 2019-05-29 2020-12-03 Université De Tours Toxoplasma platform for treating cancer
BR112022017136A2 (pt) 2020-02-28 2022-10-11 Tallac Therapeutics Inc Conjugação mediada por transglutaminase
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
US5266313A (en) * 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
DK0584266T3 (da) * 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
US5382425A (en) * 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5374149A (en) 1993-01-13 1994-12-20 Computower Technologies, Corp. Vertical storage conveyor with symmetrical motor drive system
JP3907698B2 (ja) * 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)

Similar Documents

Publication Publication Date Title
JP2001509286A5 (2)
JP2001509146A5 (2)
JP2000512098A5 (2)
JP2001513659A5 (2)
JP2001504338A5 (2)
JP2000515319A5 (2)
JP2000508322A5 (2)
JP2000511106A5 (2)
JP2000504625A5 (2)
JP2001503889A5 (2)
JP2000504908A5 (2)
JP2000510510A5 (2)
JP2001507676A5 (2)
JP2000513663A5 (2)
JP2000511697A5 (2)
JP2000503912A5 (2)
JP2000516459A5 (2)
JP2000511443A5 (2)
JP2000514543A5 (2)
JP2000514709A5 (2)
JP2001513118A5 (2)
JP2000512341A5 (2)
JP2000508673A5 (2)
JP2001508440A5 (2)
JP2001516520A5 (2)